Vol 7, Supplement 1 (February 2018): Translational Lung Cancer Research

Editorial

An innovative mesothelioma treatment based on miR-16 mimic loaded EGFR targeted minicells (TargomiRs)
Santiago Viteri, Rafael Rosell
Treatment redirection from cure to palliation, then cure again? A cautious, but urgent matter
Jhingook Kim
Emerging resistance pathways in lung cancer: what has ROS-1 taught us?
Doraid Alrifai, Martin D. Forster, Sam M. Janes
Targeting the metastatic niche through anti-angiogenic approaches in epidermal growth factor receptor mutant non-small cell lung cancer
Wan Ling Tan, Daniel S. W. Tan
PACIFIC trial: new perspectives for immunotherapy in lung cancer
Francesco Agustoni, Fred R. Hirsch
Can population data guide surveillance strategies for second primary lung cancers?
Andrew J. Arifin, Mark T. Corkum, Alexander V. Louie
Nivolumab as first-line treatment in non-small cell lung cancer patients—key factors: tumor mutation burden and PD-L1 ≥50%
Paul Zarogoulidis, Vasilis Papadopoulos, Elena Maragouli, George Papatsibas, Chrysanthi Sardeli, Yan-Gao Man, Chong Bai, Haidong Huang
Next-generation molecular therapy in lung cancer
Jun Qian, Pierre P. Massion
Putting the brakes on CTLA-4 inhibition in lung cancer?
Meghan J. Mooradian, Justin F. Gainor
Do EGFR tyrosine kinase inhibitors (TKIs) still have a role in EGFR wild-type pre-treated advanced non-small cell lung cancer (NSCLC)?—the shifting paradigm of therapeutics
Malinda Itchins, Stephen Clarke, Nick Pavlakis
Tumor heterogenicity: multiple needle biopsies from different lesion sites—key to successful targeted therapy and immunotherapy
Paul Zarogoulidis, Vasilis Papadopoulos, Elena Maragouli, George Papatsibas, Ilias Karapantzos, Chong Bai, Haidong Huang
Long-term CT surveillance after primary lung cancer treatment captures events in all risk groups
John Kang, Amit K. Chowdhry, Michael T. Milano
The risk of second primary lung cancer: an unsolved dilemma
Antoinette J. Wozniak, Ann G. Schwartz
Editorial on PanCan study
Henry M. Marshall,, Ian A. Yang, Rayleen V. Bowman, Kwun M. Fong

Meet the Professor

Prof. Lukas Bubendorf: the pros and cons of using cytology specimens in molecular testing
Brad Li, Vanessa Zhao
Prof. Nir Peled: CT first, biomarkers next
Brad Li, Lilian Xie
Dr. Lucio Crinò: our greatest challenge is finding the right treatment for the right patients
Brad Li, Bella Poon
Dr. David Ross Camidge: always be the first to see something
Brad Li, Maxine Feng
Dr. Jhingook Kim: surgeons are not merely technicians, but scientists
Brad Li
Dr. Vera Hirsh: improving patient’s quality of life is necessary for cancer treatment
Brad Li, Vicky Wong
Dr. Ignacio Gil-Bazo: family support is my key to success!
Brad Li, Vicky Wong
Professor Fred R. Hirsch, the IASLC CEO—showing you around the 18th World Conference on Lung Cancer (WCLC 2017)
Lynn Ma, Chao-Xiu(Melanie) He
Professor David Ball: prophylactic cranial irradiation (PCI) benefits patients with SCLC
Macy Liu
Professor Raymond U. Osarogiagbon: another major challenge over next decades—how to incorporate the cutting-edge diagnostics and biologic prognosticating ability into a traditionally anatomy-centered TNM staging system
Lynn Ma, Chao-Xiu(Melanie) He
Professor Fred R. Hirsch: together, our voices are much stronger than individually—a special interview about the 2017 Lung Cancer Awareness Month campaign
Chao-Xiu(Melanie) He